Scipher Medicine declares 10.4% of Chemomab through merger-linked purchase
Scipher Medicine holds 10.4% of Chemomab Therapeutics after buying shares under the merger agreement between the two companies, expected to close in the first quarter of 2027.
The filing
13D
10.4%
Of the shares
$88M
Value
Active
Investor
C
Chemomab Therapeutics Ltd. American Depositary Share
Holds 74,576,240 shares
Stated purpose
Scipher bought 932,203 ADSs at $1.18 each, about $1.1 million, to meet its financing duty under its pending merger with Chemomab, expected to close in the first calendar quarter of 2027.
Declared to the SEC, the US stock market watchdog (Schedule 13D), after the 5% threshold was crossed on November 3, filed on November 10.
AI analysis
Nov 10
With TrueWallet Pro
What this filing changes for the stock, what the fund wants, and what it does not say. Upgrade to Pro from the TrueWallet app.